AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Carvitop 3.125mg Tablet IR

Prescription Icon
Prescription Required

Marketer

Docheal Pharma Pvt Ltd

Salt Composition

Carvedilol (3.125mg)

Overview Carvitop 3.125mg Tablet IR

Cardiovasc 3.125mg Immediate-Release tablets manage hypertension, angina pectoris, and congestive heart failure. Its mechanism involves vasodilation, improving blood flow to the heart. Reduced blood pressure contributes to stroke and myocardial infarction prevention. Administer Cardiovasc 3.125mg with food, following your physician's prescribed dosage and regimen. Continue treatment even with symptom improvement or controlled blood pressure. Discontinue only under medical supervision to avoid potential worsening of your condition. Lifestyle modifications, such as regular physical activity, weight management, smoking cessation, moderated alcohol consumption, and a low-sodium diet (as directed), enhance therapeutic efficacy. While generally well-tolerated, potential side effects include vertigo, cephalalgia, dyspnea, and fatigue. Report persistent or bothersome side effects to your doctor. Prior to initiating treatment, disclose any pre-existing cardiac or renal conditions. Consult your physician before using Cardiovasc if pregnant or breastfeeding.

Primary Ingredients of Carvitop 3.125mg Tablet IR

No text provided. Please provide the text you wish me to rephrase.

Uses of Carvitop 3.125mg Tablet IR

Managing elevated blood pressure | Addressing angina pectoris | Treating congestive heart failure

Major Benefits of Carvitop 3.125mg Tablet IR:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Carvitop 3.125mg Tablet IR whole; avoid chewing, crushing, or breaking it. Administer this medicine with a meal.

Common Side effects of Carvitop 3.125mg Tablet IR:

  • Decreased blood pressure
  • Headache
  • Fatigue
  • Dizziness
  • Breathlessness

How to use Carvitop 3.125mg Tablet IR:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Carvitop 3.125mg Tablet IR whole; do not break, crush, or chew it. Administer this medication with a meal.

How Carvitop 3.125mg Tablet IR works:

Carvitop 3.125mg immediate-release tablets combine alpha and beta-blocking actions. This dual mechanism reduces heart rate and dilates blood vessels, thereby improving the heart's pumping efficiency.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Carvitop 3.125mg Tablet IR and alcohol is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Carvitop 3.125mg Immediate-Release tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any possible dangers prior to prescribing. Physician consultation is advised.

Breast feedingBreast feedingSAFE IF PRESCRIBED

The immediate-release Carvitop 3.125mg tablet is likely safe for breastfeeding mothers. Available human data indicates minimal infant risk associated with its use.

DrivingDrivingUNSAFE

Taking Carvitop 3.125mg immediate-release tablets might cause drowsiness, blurred vision, or dizziness. Refrain from driving if you experience these effects.

KidneyKidneySAFE IF PRESCRIBED

Carvitop 3.125mg immediate-release tablets can be used by patients with kidney disease without altering the dosage. Nevertheless, disclosure of any pre-existing kidney condition to your physician is advisable. Routine blood pressure checks are suggested to guide any necessary dosage modifications.

LiverLiverCAUTION

Patients with liver impairment should use Carvitop 3.125mg immediate-release tablets cautiously, potentially requiring dose modification. Consult a physician. Carvitop 3.125mg immediate-release tablets are contraindicated in individuals with severe hepatic dysfunction.

What if you forget to take Carvitop 3.125mg Tablet IR :

Should you forget a Carvitop 3.125mg Tablet IR dose, administer it promptly. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Carvitop 3.125mg Tablet IR

LabelValue
Chemical Type Carbazole-propanol derivative
Developing Habits No.
Treatment Category Heart
Active Class Alpha-beta blocker

FAQs on Carvitop 3.125mg Tablet IR

Take Carvitop 3.125mg tablets regularly as prescribed. Abruptly stopping this medication may lead to chest pain or a heart attack. Your doctor will gradually reduce your dosage before discontinuation, if necessary.
Yes, Carvitop 3.125mg Immediate-Release tablets can cause drowsiness and dizziness, especially at the start of treatment or after a dose increase. Avoid driving or operating machinery if affected.
Weight gain is a possible side effect of Carvitop 3.125mg Tablet IR, though not universal. For heart failure patients taking this medication, report any weight gain or shortness of breath to your doctor immediately, as these could indicate fluid retention.
Kidney function may rarely worsen in heart failure patients taking Carvitop 3.125mg Tablet IR. However, a higher risk of kidney failure exists in patients with low blood pressure (systolic <100 mm Hg), hardened arteries, pre-existing heart disease, or impaired kidney function. Close monitoring is crucial for these patients during treatment. Kidney function typically recovers upon discontinuation of Carvitop 3.125mg Tablet IR.
Diabetic patients can take Carvitop 3.125mg Tablet IR, but regular blood glucose monitoring is crucial. While studies show no blood glucose impact in well-controlled diabetics with mild-to-moderate hypertension, beta-blockers like Carvitop can mask hypoglycemia symptoms (e.g., increased heart rate). Furthermore, Carvitop may worsen hyperglycemia in diabetic patients with heart failure. Therefore, close blood glucose monitoring is essential when starting, adjusting, or stopping Carvitop. Report any blood glucose changes to your doctor.
Taking Carvitop 3.125mg Tablet IR with food is advised. Food slows absorption, minimizing the risk of orthostatic hypotension (dizziness or fainting upon standing).
Carvitop 3.125mg Immediate-Release Tablets can cause serious side effects, including fainting, shortness of breath, weight gain, and swelling in the extremities (arms, hands, feet, ankles, or lower legs). Other possible side effects are chest pain, abnormal heart rhythm, rash, hives, itching, and difficulty breathing or swallowing. Seek immediate medical attention if any of these occur.
Exceeding the recommended dose of Carvitop 3.125mg Tablet IR can lead to slowed heart rate, dizziness, fainting, shortness of breath, vomiting, and potentially loss of consciousness or seizures. Seek immediate medical attention at a hospital, contacting your doctor first.
Carvitop 3.125mg Tablet IR is contraindicated in patients with severe heart failure requiring intensive care or inotropic support, those with asthma or other respiratory issues, bradycardia or arrhythmias, liver impairment, or known allergy to Carvitop 3.125mg Tablet IR.
Carvitop 3.125mg Tablet I...
25
MRP 30
16% off